ARTICLE | Finance
With $88M series B, Spruce seeks short path to approval in rare endocrine disorder
Four-year-old Spruce chose an investor syndicate with experience in rare diseases and public markets
February 20, 2020 10:14 PM UTC
Updated on Feb 21, 2020 at 3:39 PM UTC
Spruce Biosciences hopes two rounds of financing will be enough to deliver pivotal data for its lead program, which takes a non-steroidal approach to treating endocrine disorders such as classic congenital adrenal hyperplasia (CAH).
Omega Funds and Abingworth co-led the new $88 million series B round for Spruce Biosciences Inc., announced late Wednesday. Joining them were existing investors Novo Holdings A/S and RiverVest Venture Partners, as well as first-time backers HealthCap Partners, Rock Springs Capital, Citadel’s Surveyor Capital, Aisling Capital and Sands Capital...
BCIQ Company Profiles